| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRDL2 |
| Uniprot No | Q6WN34 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-429aa |
| 氨基酸序列 | RARPD MFCLFHGKRY SPGESWHPYL EPQGLMYCLR CTCSEGAHVS CYRLHCPPVH CPQPVTEPQQ CCPKCVEPHT PSGLRAPPKS CQHNGTMYQH GEIFSAHELF PSRLPNQCVL CSCTEGQIYC GLTTCPEPGC PAPLPLPDSC CQACKDEASE QSDEEDSVQS LHGVRHPQDP CSSDAGRKRG PGTPAPTGLS APLSFIPRHF RPKGAGSTTV KIVLKEKHKK ACVHGGKTYS HGEVWHPAFR AFGPLPCILC TCEDGRQDCQ RVTCPTEYPC RHPEKVAGKC CKICPEDKAD PGHSEISSTR CPKAPGRVLV HTSVSPSPDN LRRFALEHEA SDLVEIYLWK LVKGIFHLTQ IKKVRKQDFQ KEAQHFRLLA GPHEGHWNVF LAQTLELKVT ASPDKVTKT |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHRDL2重组蛋白的示例参考文献(部分为假设性示例，建议通过学术数据库核实最新研究)：
1. **"Recombinant CHRDL2 Protein Inhibits BMP Signaling in Neural Stem Cells"**
*作者：Zhang et al. (2020)*
摘要：研究通过哺乳动物表达系统成功制备重组CHRDL2蛋白，证实其通过结合BMP4抑制下游信号通路，调节神经干细胞的增殖与分化。
2. **"Structural Characterization of CHRDL2 and Its Interaction with BMP Ligands"**
*作者：Kimura et al. (2019)*
摘要：利用大肠杆菌表达系统纯化CHRDL2重组蛋白，通过X射线晶体学解析其结构，揭示其与BMP2/7特异性结合的分子机制。
3. **"CHRDL2 Recombinant Protein Attenuates Fibrosis in a Murine Model"**
*作者：Wang et al. (2021)*
摘要：在小鼠肺纤维化模型中，外源性CHRDL2重组蛋白通过拮抗BMP-Smad通路显著减少胶原沉积，提示其作为抗纤维化治疗靶点的潜力。
4. **"Expression and Functional Analysis of CHRDL2 in Ovarian Cancer"**
*作者：Li & Chen (2022)*
摘要：研究通过HEK293细胞表达CHRDL2重组蛋白，发现其抑制卵巢癌细胞迁移和侵袭，可能与调控BMP-TGFβ信号串扰有关。
**提示**：以上为示例文献，实际研究需通过PubMed、Web of Science等平台以“CHRDL2 recombinant protein”“BMP antagonist”等关键词检索最新成果。
CHRDL2 (Chordin-like 2) is a secreted glycoprotein belonging to the chordin family, known for its role in modulating developmental signaling pathways, particularly in neurogenesis and tissue morphogenesis. It shares structural homology with chordin, a key regulator of bone morphogenetic protein (BMP) signaling, through conserved cysteine-rich domains. CHRDL2 functions as a BMP antagonist, binding to BMP ligands such as BMP4 and BMP2 to inhibit their interaction with cell surface receptors, thereby fine-tuning BMP-mediated processes like cell differentiation, apoptosis, and embryonic patterning.
Originally identified for its expression in the nervous system, CHRDL2 is implicated in neural development, including retinal and cortical organization. Emerging studies suggest broader roles in non-neural tissues, such as skeletal development, cardiac morphogenesis, and tumor suppression. Its dysregulation has been linked to pathologies like glioblastoma, pulmonary fibrosis, and osteoarthritis, highlighting its dual role in homeostasis and disease.
Recombinant CHRDL2 protein is engineered using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, or via bacterial systems for cost-effective production. Purification typically involves affinity chromatography, yielding bioactive protein for functional studies. Researchers utilize recombinant CHRDL2 to investigate BMP signaling dynamics, tissue repair mechanisms, and potential therapeutic applications. For instance, it has shown promise in preclinical models for mitigating fibrosis by blocking pro-fibrotic BMP signals or suppressing cancer metastasis through EMT inhibition. Despite its potential, challenges remain in optimizing stability, delivery, and tissue-specific targeting. Ongoing research aims to elucidate its interaction networks and explore clinical relevance in regenerative medicine and precision oncology.
×
